INSM — INSMED Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1104506 ·
Last close
$121.86
Market Cap
$26.73B
52W High
$212.75
52W Low
$90.39
ADV30
3,443,297
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 524,428,000 446,213,000 -81,829,000 -100,319,000 2,226,056,000 396,563,000 1,499,842,000
Jun 2026 425,486,000 358,274,000 -101,308,000 -13,242,000 2,102,565,000 544,765,000 1,345,071,000
Mar 2026 305,964,000 258,544,000 -200,281,000 -163,563,000 2,075,863,000 582,188,000 1,371,011,000
Dec 2025 263,843,000 219,623,000 -249,708,000 -328,485,000 2,264,558,000 510,445,000 1,525,582,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-595,622,000
Investing CF
$543,796,000
Financing CF
$114,189,000
CapEx
$-31,953,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.82
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-5,913,816,000
Inventory
$163,946,000
Receivables
$259,270,000
ST Investments
$750,063,000
EBIT TTM
$-522,361,000
Pretax Income TTM
$-598,058,000
Interest Exp TTM
$75,697,000
Analysts
22

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,519,720,960
EBITDA
$-611,032,000
Free Cash Flow
$-456,756,256
Enterprise Value
$24,282,144,768
Total Cash
$1,146,626,048
Total Debt
$730,936,000
Shares Out
219,380,309
Trailing EPS
$-4.10
Book Value
$3.31
ROE
-72.5%
ROA
-17.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 606,423,000 -994,776,000 -1,276,775,000 2,264,558,000 1,525,582,000 738,976,000 -935,014,000
Dec 2024 363,707,000 -786,570,000 -913,772,000 2,025,231,000 1,739,852,000 285,379,000 -683,882,000
Dec 2023 305,208,000 -680,929,000 -749,567,000 1,329,837,000 1,661,760,000 -331,923,000 -536,247,000
Dec 2022 245,358,000 -478,123,000 -481,534,000 1,656,435,000 1,568,484,000 87,951,000 -400,439,000

TTM Snapshot

Revenues TTM
$1,137,635,000
NetIncome TTM
$-875,311,000
OpCashFlow TTM
—
Assets (Latest)
$2,102,565,000
Forward EPS
$0.75

Max Pain — expiry 2027-01-15

max pain strike: $100.00 · spot: $119.80 · call oi: 44,866 · put oi: 16,317
Expected Move to 2027-01-15: ±$20.75 (17.32%) — implied range $99.05 – $140.55 · ATM straddle on $120.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ROIV Roivant Sciences Ltd. $28.05B $38.71 —
UTHR UNITED THERAPEUTICS Corp $24.88B $584.10 —
VTRS Viatris Inc $23.45B $20.45 —
RPRX Royalty Pharma plc $30.58B $68.68 —
GMAB GENMAB A/S $31.95B $51.96 —

News headlines (Yahoo Finance, 1h cache)

Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead
2026-11-17 07:12 · Yahoo
The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
2026-11-11 06:36 · Yahoo
Nanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory Affairs
2026-11-05 12:03 · Yahoo
Insmed to Present at November and December 2026 Investor Conferences
2026-11-04 12:00 · Yahoo
Insmed (INSM) Lifts Guidance After Earnings As Fair Value Debate Heats Up
2026-10-31 16:09 · Yahoo
Insmed (INSM) Begins BRINSUPRI Sales In Japan
2026-10-31 01:17 · Yahoo
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
2026-10-30 13:29 · Yahoo
Insmed Incorporated Q3 2026 Earnings Call Summary
2026-10-30 12:30 · Yahoo
Why Did Insmed Stock Jump?
2026-10-30 11:15 · Yahoo
Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”
2026-10-29 18:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.